Investigational drug · Phase 2
HW201877
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Inflammatory Bowel Disease (IBD).
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "HW201877"
First trial start
2026
Nov 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "HW201877", any sponsor or status.
Conditions studied
As listed on its trial records.
- Inflammatory Bowel Disease (IBD)
Approved drugs for the same conditions: Immunology and inflammation · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "HW201877" as an intervention, largest first.
- A Phase I Study of HW201877 in Healthy SubjectsPivotal-lookingRecruiting
Wuhan Humanwell Innovative Drug Research and Development Center Limited CompanyIndustry
NCT07373457 · 104 participants (planned) · Start Jun 26, 2025 · Primary completion Mar 2026
Drug: HW201877 capsules; Placebo · For: Healthy Participants; IBD (Inflammatory Bowel Disease)
Sites: Changchun, China
- A Study of HW201877 Capsules for Participants With Moderate to Severe Active Inflammatory Bowel Disease (IBD)Not yet recruiting
Hubei Bio-Pharmaceutical Industrial Technological Institute Inc.Industry
NCT07942766 · 40 participants (planned) · Start Nov 2026 · Primary completion Dec 2027
Drug: HW201877 capsules · For: Inflammatory Bowel Disease (IBD)
Sites: Wuhan, China
Newest research
PubMed records naming it or its code names, newest first.
- Discovery of HW201877: A Highly Potent and Orally Bioavailable Inhibitor of 15-Prostaglandin Dehydrogenase to Potentiate Tissue Repair and Regeneration.
Li Q, Zang Y, An D, et al. · J Med Chem 2025
Also in development for Inflammatory Bowel Disease (IBD)
- DISC-0974Phase 22 trials
Disc Medicine, Inc · Anemia, Inflammatory Bowel Disease (IBD), Inflammatory Bowel Disease (IBD); Anemia
- MT-201Phase 21 trial
Mirador Therapeutics, Inc. · Inflammatory Bowel Disease (IBD), Ulcerative Colitis (UC), Crohn's Disease
- MT-501Phase 21 trial
Mirador Therapeutics, Inc. · Inflammatory Bowel Disease (IBD), Ulcerative Colitis (UC), Crohn's Disease
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.